NCT07135453PHASE4RecruitingAccepts Healthy Volunteers

Induction of Cross-protective Antibodies for Serogroup 33 by Pneumococcal Conjugate Vaccines

University of Alabama at Birmingham

Start Date

7/1/2026

Completion Date

8/1/2027

Summary

The goal of this study is to learn whether different types of vaccines to prevent bacterial infections are able to effectively create antibodies that defend against certain types of bacteria. We will give two different types of vaccine and evaluate the effectiveness of antibodies produced by each vaccine in killing bacteria.

Eligibility Criteria

Age Range: 18 years to No maximum

Inclusion Criteria: * Healthy adult Exclusion Criteria: * No prior history of pneumococcal vaccination * No immunosuppressing medications or chronic diseases that affect immune function

Interventions

BIOLOGICAL

Pneumococcal Vaccine

Interested in This Trial?

Contact the trial locations directly using the information below to learn more about enrollment.

Expressing interest lets you review the study and consent before we connect you with the research site.

Conditions

VaccinePneumococcal Disease

Locations

University of Alabama at Birmingham

Birmingham, Alabama 35294

United States

Run studies, or work at a research site?

Corterve helps sites and sponsors reach patients who are looking for trials. It does not determine eligibility and does not promise an enrolment outcome.

For sponsors, CROs and sites

What Corterve sells to organisations, and the anti-kickback constraints it works within.

Services and published prices

Lay summaries for EU CTR Annex V, pre-screen filtration, recruitment-creative regulatory operations, feasibility reporting.

For research sites

One published licence rate, the same for every site, and the fees a site is never charged.